What is Arcascope?
Founded in 2020, Arcascope operates at the vanguard of healthcare technology, specifically targeting the optimization of circadian rhythms. The company utilizes advanced analytics to translate complex biological data into actionable health strategies. By focusing on the timing of biological processes, Arcascope aims to improve patient outcomes in environments ranging from clinical settings to daily wellness management. Their market position is defined by a unique synthesis of deep-tech machine learning and chronobiology, placing them in a distinct category within the broader digital health ecosystem.
How much funding has Arcascope raised?
Arcascope has raised a total of $2.9M across 1 funding round:
Angel/Seed
$2.9M
Angel/Seed (2022): $2.9M with participation from New Dominion Angels, AIoT Health, Inflect Health, Inception Health, and Supermoon Capital
Key Investors in Arcascope
New Dominion Angels
A Washington, DC-based investment group comprised of experienced entrepreneurs and executives who focus on scaling early-stage startups within the Mid-Atlantic region.
AIoT Health
A specialized syndicate fund that leverages deep technology and machine learning to support early-stage ventures dedicated to advancing personalized medicine.
Supermoon Capital
A venture capital platform exclusively dedicated to the sleep and wellness sector, supporting founders who are innovating at the intersection of technology and human rest.
What's next for Arcascope?
With the infusion of this major enterprise-level funding, Arcascope is poised to scale its operational infrastructure and expand its clinical validation efforts. The strategic roadmap likely involves deepening its integration with existing healthcare delivery systems and refining its algorithmic models to support personalized medicine initiatives. As the company matures, the focus will shift toward establishing long-term partnerships with health systems and wellness providers, ensuring that their circadian-focused technology becomes a standard component of preventative and therapeutic care. The backing from specialized investors suggests a clear trajectory toward market leadership in the sleep and biological rhythm sector.
See full Arcascope company page
